<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>gene &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/gene/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Mon, 29 Apr 2024 07:14:34 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>gene &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>The FDA approves Pfizer&#039;s first gene therapy for the rare inherited bleeding disorder</title>
		<link>https://bloggingthree.soflytech.com/2024/04/the-fda-approves-pfizers-first-gene-therapy-for-the-rare-inherited-bleeding-disorder/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Mon, 29 Apr 2024 07:14:34 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[approves]]></category>
		<category><![CDATA[bleeding]]></category>
		<category><![CDATA[disorder]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[inherited]]></category>
		<category><![CDATA[Pfizer39s]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[therapy]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=1958</guid>

					<description><![CDATA[The Food and Drug Administration on Friday announced that the agency had agreed Pfizeris the treatment of a rare genetic disease Blood clotting disorderwhat makes it an organization first gene therapy to acquire clearance within the USA The Agency given the green light the drug, marketed as Beqvez, is meant for adults with moderate to [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div>
<p>The Food and Drug Administration <a href="https://www.businesswire.com/news/home/20240425269649/en/U.S.-FDA-Approves-Pfizer%E2%80%99s-BEQVEZ%E2%84%A2-fidanacogene-elaparvovec-dzkt-a-One-Time-Gene-Therapy-for-Adults-with-Hemophilia-B" target="_blank" rel="noopener">on Friday</a> announced that the agency had agreed <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-2">Pfizer<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>is the treatment of a rare genetic disease <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study" target="_blank" rel="noopener">Blood clotting disorder</a>what makes it an organization <a href="https://www.pfizer.com/news/press-release/press-release-detail/fda-accepts-pfizers-application-hemophilia-b-gene-therapy" target="_blank" rel="noopener">first gene therapy</a> to acquire clearance within the USA </p>
<p>The Agency <a href="https://www.businesswire.com/news/home/20240425269649/en/U.S.-FDA-Approves-Pfizer%E2%80%99s-BEQVEZ%E2%84%A2-fidanacogene-elaparvovec-dzkt-a-One-Time-Gene-Therapy-for-Adults-with-Hemophilia-B" target="_blank" rel="noopener">given the green light</a> the drug, marketed as Beqvez, is meant for adults with moderate to severe disease <a href="https://www.bleeding.org/bleeding-disorders-a-z/types/hemophilia-b" target="_blank" rel="noopener">Hemophilia B</a> the certain ones meet <a href="https://www.businesswire.com/news/home/20240425269649/en/U.S.-FDA-Approves-Pfizer%E2%80%99s-BEQVEZ%E2%84%A2-fidanacogene-elaparvovec-dzkt-a-One-Time-Gene-Therapy-for-Adults-with-Hemophilia-B" target="_blank" rel="noopener">Requirements</a>.</p>
<p>The treatment can be available by prescription for eligible patients this quarter, a Pfizer spokesperson told CNBC.  The spokesperson added that the value is a hefty $3.5 million, making it one of the crucial expensive drugs within the United States, the spokesperson added</p>
<p>More than 7,000 people within the United States live with debilitating illnesses <a href="https://www.bleeding.org/bleeding-disorders-a-z/types/hemophilia-b" target="_blank" rel="noopener">Condition</a>which, based on one, predominantly affects men <a href="https://www.hemob.org/about-hemophilia-b" target="_blank" rel="noopener">Advocacy</a>.  The condition is brought on by insufficient amounts of a <a href="https://rarediseases.org/rare-diseases/hemophilia-b/" target="_blank" rel="noopener">certain protein</a> This helps blood clot to stop bleeding and seal wounds.  Without this protein, called factor IX, patients with hemophilia B bruise more easily and bleed more continuously and for longer periods of time. </p>
<p>Beqvez is a one-time treatment designed to enable patients to provide factor IX themselves and stop and control bleeding.  In a late-stage trial, the drug was found to be superior to the usually cumbersome <a href="https://pubmed.ncbi.nlm.nih.gov/10605746/" target="_blank" rel="noopener">Standard treatment</a> in hemophilia B, wherein the protein is run through the veins several times every week or month. </p>
<p>“Many people with hemophilia B struggle with commitment and disruption to their lifestyle [factor IX] infusions as well as spontaneous bleeding episodes that can lead to painful joint damage and mobility problems,” Adam Cuker, director of Penn Medicine’s Comprehensive and Hemophilia Thrombosis Program, said in a Pfizer statement <a href="https://www.businesswire.com/news/home/20240425269649/en/U.S.-FDA-Approves-Pfizer%E2%80%99s-BEQVEZ%E2%84%A2-fidanacogene-elaparvovec-dzkt-a-One-Time-Gene-Therapy-for-Adults-with-Hemophilia-B" target="_blank" rel="noopener">release</a> on Friday.</p>
<p>Pfizer&#39;s drug &#8220;has the potential to be transformative for eligible patients by reducing both the medical and treatment burden in the long term,&#8221; Cuker added. </p>
<p>The approval is a giant step for Pfizer, which is attempting to regain its footing after the rapid decline in its Covid business last 12 months.  The company is betting heavily on cancer drugs and coverings for other disease areas to show around its business. </p>
<p>Pfizer is one in every of several firms investing within the fast-growing field of gene and cell therapies — one-time, expensive treatments that concentrate on a patient&#39;s genetic source or cell to cure or significantly alter the course of a disease.  Some health experts expect these therapies to interchange traditional lifelong treatments that folks take to treat chronic illnesses. </p>
<p>Pfizer <a href="https://www.prnewswire.com/news-releases/spark-therapeutics-announces-gene-therapy-collaboration-in-hemophilia-b-with-pfizer-inc-300005849.html" target="_blank" rel="noopener">gained the rights</a> 2014 to provide and commercialize Beqvez from Spark Therapeutics. </p>
<p>The company offers payers a guarantee program to cover patients who receive Beqvez, a spokesperson told CNBC.  Pfizer expects this program to “provide financial protection by insuring against the risk of efficacy failure,” the press release states.</p>
<p>The gene therapy will compete with Australia-based CSL Behring <a href="https://newsroom.csl.com/2023-12-11-CSL-Behrings-HEMGENIX-R-etranacogene-dezaparvovec-drlb-Demonstrates-at-Three-Years-Post-Treatment-Long-Term-Durability,-Safety-and-Greater-Bleed-Protection-Versus-Prophylactic-Treatment-in-People-Living-with-Hemophilia-B" target="_blank" rel="noopener">Hemgenix</a>the same treatment that<a href="https://www.fiercepharma.com/pharma/csl-and-uniqures-hemophilia-b-gene-therapy-scores-approval-35-million-price-tag" target="_blank" rel="noopener"> has received FDA approval</a> for hemophilia B in 2022. This drug has the same list price within the US of $3.5 million before insurance and other discounts. </p>
<p>In particular, some health experts have identified that that is due, amongst other things, to high costs and logistical problems<a href="https://www.reuters.com/business/healthcare-pharmaceuticals/uptake-new-hemophilia-gene-therapies-slow-field-assesses-options-2023-12-15/" target="_blank" rel="noopener"> limited the intake</a> from Hemgenix and one other approved gene therapy for the more common hemophilia A. </p>
<p>Pfizer can be looking for FDA approval for its experimental antibody marstacimab to treat hemophilia A and B. The company can be developing a gene therapy for Duchenne muscular dystrophy, a genetic disorder that causes the gradual weakening of muscles. </p>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107261567-1687527022611-gettyimages-1256041032-PGONCHAR_4856.jpeg?v=1714104334&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Walgreens helps bring cell and gene therapies to patients by expanding specialty pharmacy services</title>
		<link>https://bloggingthree.soflytech.com/2024/04/walgreens-helps-bring-cell-and-gene-therapies-to-patients-by-expanding-specialty-pharmacy-services/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Thu, 25 Apr 2024 07:02:34 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[bring]]></category>
		<category><![CDATA[cell]]></category>
		<category><![CDATA[expanding]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[helping]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmacy]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[specialty]]></category>
		<category><![CDATA[therapies]]></category>
		<category><![CDATA[Walgreens]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=1536</guid>

					<description><![CDATA[Walgreens announced Thursday that it would work directly with drugmakers to bring cell and gene therapies to U.S. patients as a part of a broader expansion Services of a specialty pharmacy. The company announced that it&#8217;s establishing a brand new business unit for its specialty pharmacy segment, which can include a specialty pharmacy subsidiary AllianceRx. [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Walgreens<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span><strong> </strong>announced Thursday that it would work directly with drugmakers to bring cell and gene therapies to U.S. patients as a part of a broader expansion <a href="https://www.walgreens.com/topic/pharmacy/specialty-pharmacy.jsp#how_it_works" target="_blank" rel="noopener">Services of a specialty pharmacy</a>.</p>
<p>The company announced that it&#8217;s establishing a brand new business unit for its specialty pharmacy segment, which can include a specialty pharmacy subsidiary <a href="https://www.alliancerxwp.com/" target="_blank" rel="noopener">AllianceRx</a>.<strong> </strong>The unit will likely be a part of the core business of the US pharmacy retail division.  In the meantime, <a href="https://shieldshealthsolutions.com/shields-health-solutions-and-sharp-healthcare-partner-to-enhance-specialty-pharmacy-services/" target="_blank" rel="noopener">Shields Health Solutions</a>a subsidiary that supports specialty pharmacies owned by the health system will remain under Walgreens&#39; U.S. health care division. </p>
<p>Specialty pharmacies have turn into a significant player within the U.S. healthcare system, particularly in terms of chronic diseases <a href="https://news.un.org/en/story/2023/05/1136832" target="_blank" rel="noopener">turn into more common</a>.</p>
<p>Specialty pharmacies offer medications that require extreme care in handling, storage, and distribution.  Treatments are sometimes geared toward patients with chronic, rare or complex diseases equivalent to cancer, Crohn&#39;s disease and HIV.  Specialty pharmacies also offer counseling or financial assistance to assist patients with these costly treatments.</p>
<p>The company&#39;s latest investments to &#8220;transform&#8221; its specialty pharmacy services include the opening of a newly licensed facility in Pittsburgh specializing in cell and gene therapy services.  The 18,000 square meter center will help drug manufacturers and healthcare providers, amongst others, navigate the complex supply chain for these treatments and manage patient needs.</p>
</div>
<div class="group">
<p>Walgreens&#39; decision to launch cell and gene therapy services comes after a surge in approvals of those drugs within the U.S. and European Union last 12 months.  They are <a href="https://phrma.org/policy-issues/Research-and-Development/Cell-and-Gene-Therapies#:~:text=Cell%20and%20gene%20therapies%20have,two%20FDA%2Dapproved%20gene%20therapies." target="_blank" rel="noopener">one-off, cost-intensive treatments</a> that focus on a patient&#39;s genetic source or cell to cure or significantly alter the course of a disease.  Some health experts expect cell and gene therapies to switch the normal lifelong treatments that individuals use to treat chronic diseases. </p>
<p>The US Food and Drug Administration (FDA) approved seven cell and gene therapies last 12 months, including the primary gene therapies to treat sickle cell disease.  This market is just expected to grow: the FDA has done so <a href="https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics" target="_blank" rel="noopener">predicted</a> that it would review and approve between 10 and 20 cell and gene therapies yearly by 2025. </p>
<p>Walgreens said its newly formed unit can be the most important independent provider of specialty pharmacy services, with sales of about $24 billion within the segment.  The Walgreens Specialty Pharmacy store isn&#8217;t affiliated with a pharmacy profit manager.<strong> </strong>the corporate noted. </p>
<p>That gives the corporate “the flexibility to dynamically contract with any payer,” Walgreens Chief Pharmacy Officer Rick Gates said in the discharge.  “We can work directly with pharmaceutical manufacturers to facilitate the launch of products, including drugs with limited distribution, and coordinate closely with providers to ensure patients experience a smooth start to treatment.” </p>
<p>Under the brand new entity, patients at AllianceRx and the corporate&#39;s nearly 300 community-based pharmacies will now have access to resources that &#8220;build on the expert care they already receive from their specialty pharmacist,&#8221; Walgreens said in the discharge.  These include clinicians with key disease expertise, nutritionists and nurses.</p>
<p>The company said they&#8217;re community-based specialty pharmacies<strong> </strong>are positioned near medical office buildings and health systems and offer specialty medications “faster than industry average” in addition to services equivalent to injection training and side effect management. </p>
<p>Walgreens said that was the case<strong> </strong>greater than 1,500 specialty pharmacists, 5,000 patient support team members, and an unspecified variety of dedicated specialty pharmacy teams.</p>
<p>In addition, the corporate offers greater than 1,300 specialty medicines, including 240 “limited distribution” medicines to which only a couple of specialty pharmacies have access.</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-1">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">Don&#39;t miss these exclusives from CNBC PRO</h2>
</div>
</div>
</div>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107389746-17108853292021-11-26t230341z_260294221_rc2i2r9k1xeo_rtrmadp_0_walgreens-boots-results.jpeg?v=1713214955&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
	</channel>
</rss>
